Cargando…
Teprotumumab in thyroid eye disease: wonder drug or great divider?
Progress in the management of thyroid eye disease (TED) has been slow for many decades. The recent introduction of teprotumumab (TEP) in the therapeutic arena for TED has had a major impact in view of its efficacy, particularly with respect to its ability to reduce proptosis. However, the high cost...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Bioscientifica Ltd
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10305462/ https://www.ncbi.nlm.nih.gov/pubmed/37043369 http://dx.doi.org/10.1530/ETJ-23-0043 |
_version_ | 1785065739569332224 |
---|---|
author | Perros, Petros Hegedüs, Laszlo |
author_facet | Perros, Petros Hegedüs, Laszlo |
author_sort | Perros, Petros |
collection | PubMed |
description | Progress in the management of thyroid eye disease (TED) has been slow for many decades. The recent introduction of teprotumumab (TEP) in the therapeutic arena for TED has had a major impact in view of its efficacy, particularly with respect to its ability to reduce proptosis. However, the high cost of TEP, limited availability to patients outside the USA, and the lack of data on cost-effectiveness are significant barriers to improving the care of patients with TED globally. Recent guidance from authoritative professional organisations deliver different perspectives on the role of TEP in the routine management of patients with TED, underscoring the complexities of interpreting the evidence. The advance that TEP undoubtedly represents in managing TED effectively has highlighted inequities faced by patients and uncertainties about appropriate metrics of efficacy. Professional organisations have an important role addressing these problems. Future studies need to focus on optimising the measurement of outcomes and on assessing cost-effectiveness. |
format | Online Article Text |
id | pubmed-10305462 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Bioscientifica Ltd |
record_format | MEDLINE/PubMed |
spelling | pubmed-103054622023-06-29 Teprotumumab in thyroid eye disease: wonder drug or great divider? Perros, Petros Hegedüs, Laszlo Eur Thyroid J Commentary Progress in the management of thyroid eye disease (TED) has been slow for many decades. The recent introduction of teprotumumab (TEP) in the therapeutic arena for TED has had a major impact in view of its efficacy, particularly with respect to its ability to reduce proptosis. However, the high cost of TEP, limited availability to patients outside the USA, and the lack of data on cost-effectiveness are significant barriers to improving the care of patients with TED globally. Recent guidance from authoritative professional organisations deliver different perspectives on the role of TEP in the routine management of patients with TED, underscoring the complexities of interpreting the evidence. The advance that TEP undoubtedly represents in managing TED effectively has highlighted inequities faced by patients and uncertainties about appropriate metrics of efficacy. Professional organisations have an important role addressing these problems. Future studies need to focus on optimising the measurement of outcomes and on assessing cost-effectiveness. Bioscientifica Ltd 2023-04-11 /pmc/articles/PMC10305462/ /pubmed/37043369 http://dx.doi.org/10.1530/ETJ-23-0043 Text en © the author(s) https://creativecommons.org/licenses/by-nc-nd/4.0/This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. (https://creativecommons.org/licenses/by-nc-nd/4.0/) |
spellingShingle | Commentary Perros, Petros Hegedüs, Laszlo Teprotumumab in thyroid eye disease: wonder drug or great divider? |
title | Teprotumumab in thyroid eye disease: wonder drug or great divider? |
title_full | Teprotumumab in thyroid eye disease: wonder drug or great divider? |
title_fullStr | Teprotumumab in thyroid eye disease: wonder drug or great divider? |
title_full_unstemmed | Teprotumumab in thyroid eye disease: wonder drug or great divider? |
title_short | Teprotumumab in thyroid eye disease: wonder drug or great divider? |
title_sort | teprotumumab in thyroid eye disease: wonder drug or great divider? |
topic | Commentary |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10305462/ https://www.ncbi.nlm.nih.gov/pubmed/37043369 http://dx.doi.org/10.1530/ETJ-23-0043 |
work_keys_str_mv | AT perrospetros teprotumumabinthyroideyediseasewonderdrugorgreatdivider AT hegeduslaszlo teprotumumabinthyroideyediseasewonderdrugorgreatdivider |